With shares languishing near $5.74, Bausch Health Companies (BHC) presents a stark valuation puzzle. While a standard DCF model suggests a staggering 91% undervaluation, the market's persistent sell-off reflects deep-seated concerns over the company's restructuring path and debt burden. We examine the numbers behind the divergence.
AXIS Capital Holdings (AXS) shares have surged 15% over the past year, closing at $103.18 and reigniting discussions about its valuation. Analysts see a potential upside to $121, but the market weighs risks from cyber claims and social inflation.
As Apple's stock experiences recent volatility, investors are grappling with a critical question: does its current price reflect its long-term potential? A deep dive into valuation models reveals a complex picture, with traditional metrics painting conflicting signals about the iPhone maker's true worth.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
After years of heavy investment in organic growth, midstream giant Enterprise Products Partners signals a strategic shift, slashing future capital expenditures and ramping up buybacks to return more cash to investors.
Faced with the realities of modern warfare in Ukraine, NATO is fast-tracking innovation, creating an unprecedented opportunity for agile tech founders to access a once-closed defense market.
While investor attention fixates on flashier names, Marvell Technology's critical role in custom AI chips and data center infrastructure positions it for explosive growth, making its current valuation a potential opportunity.
An analysis of wealth accumulation among the world's top billionaires reveals staggering gains during the current presidential term, with policy and market dynamics fueling unprecedented fortunes.
Peter Mandelson, former UK ambassador to Washington, has resigned from the Labour Party following the release of US court documents detailing financial links to the late financier and convicted sex offender Jeffrey Epstein.
Amid a steep 60% annual share price decline, investment firm Chicago Capital has significantly reduced its position in PROCEPT BioRobotics, a developer of robotic systems for urological surgery, signaling a portfolio risk reassessment.
The Biden administration has approved a major arms sale to Israel, featuring attack helicopters and armored vehicles, amid a fragile ceasefire in Gaza and ongoing scrutiny over U.S. military support.
In a rare firsthand account, Dr. Mohamed Ibrahim details his three-day escape from el-Fasher as paramilitary forces overran the city. His testimony paints a harrowing picture of urban warfare, civilian slaughter, and the systematic collapse of Sudan's last army bastion in Darfur.
Exclusive testimony from Dr. Mohamed Ibrahim, who fled the last hospital in Sudan's strategic el-Fasher, details a three-day ordeal of hiding from paramilitary forces, witnessing mass casualties, and surviving a kidnapping and ransom demand—shedding light on a siege the U.N. calls a 'massive crime scene.'
Amid a brutal year for apparel stocks, Deckers Outdoor delivered a stunning earnings beat, sending shares soaring 19%. The performance of its HOKA and UGG brands, coupled with raised guidance, suggests Wall Street's pessimism may have been overblown for this long-term winner.
General Motors is cutting over 700 positions at its Oshawa, Ontario plant, redirecting investment and workforce development to its U.S. facilities. The move underscores a strategic realignment of North American operations amid evolving trade dynamics and a focus on core truck and SUV programs.
Greenlight Capital has spotlighted Core Natural Resources (CNR), the entity formed from the merger of Arch Resources and CONSOL Energy, as a key coal investment. The fund cites the company's valuation and combined asset base, even as the sector grapples with operational challenges. This endorsement brings renewed scrutiny to CNR's integration path and its strategy in a complex market.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
A revised price target for Haivision Systems (TSX:HAI) is shifting the investment narrative, prompting a closer look at the video streaming technology firm's prospects amid evolving market conditions.
Shares of Charter Communications jumped more than 7% Friday after the telecom giant reported a smaller-than-anticipated decline in internet subscribers for the fourth quarter, signaling resilience in its core business amid industry-wide pressures.
In a major consolidation move within the quantum computing sector, IonQ has announced a definitive agreement to acquire U.S.-based semiconductor foundry SkyWater Technology for $1.8 billion. The deal aims to create a domestically controlled, vertically integrated platform to speed up the development and production of advanced quantum processors, citing both technological and national security imperatives.
